Analyst upgrades and downgrades can be highly influential on stock prices. Stocks like these can provide short-term profits, but they can also result in investment losses if analysts downgrade them or even misjudge them.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Three tiers are commonly used by analysts to rate stocks:
Analysts who rate a stock “Buy” expect it to outperform the market. It is also possible for analysts to use ratings such as overweight and outperform.
Generally, analysts assign a “Hold” rating to stocks if they anticipate them to perform similarly to the market. “Hold” ratings mean a stock is not recommended for trading at this moment. This rating is also known as Market Perform or Equal Weight.
In the world of investing, analysts label stocks as “Sell” when they expect them to fall short of expectations. Stocks are rarely rated “Sell” by analysts since most give them positive or Neutral ratings. Underweight and underperform can also be used by analysts when rating a stock “Sell”.
Looking at the support for BorgWarner Inc. (NYSE: BWA), a number of firms have released research notes about the stock. Exane BNP Paribas stated their Outperform rating for the stock in a research note on December 07, 2022, with the firm’s price target at $49. Morgan Stanley coverage for the BorgWarner Inc. (BWA) stock in a research note released on November 28, 2022, offered an Equal-weight rating with a price target of $45. Deutsche Bank was of the view on July 18, 2022, that the stock is Buy, while Exane BNP Paribas gave the stock a Neutral rating on April 11, 2022. Jefferies on their part issued a Hold rating on September 20, 2021.
The shares of Allscripts Healthcare Solutions Inc. (NASDAQ: MDRX) have been pegged with a rating of Buy by Argus in its latest research note that was published on December 07, 2022. The Healthcare company has also assigned a $26 price target. Argus wasn’t the only research firm that published a report on Allscripts Healthcare Solutions Inc., with other equities research analysts also giving their opinion on the stock. Goldman advised investors in its research note published on November 09, 2022, to “Buy,” the MDRX stock while also putting a $23 price target. The stock had earned an Overweight rating from Piper Sandler when it published its report on November 04, 2022. That day Piper Sandler set a price target on the stock to $17. The stock was given a Sector Weight rating by KeyBanc Capital Markets in its report released on September 16, 2022. Goldman was of the view that MDRX is Neutral in its latest report on July 12, 2022. Deutsche Bank thinks that MDRX is worth a Buy rating. This was contained in the firm’s report on March 04, 2022, in which the stock’s price target was also moved to 26.
Investment analysts at Raymond James published a research note on December 07, 2022, where it informed investors and clients that Tradeweb Markets Inc. (NASDAQ: TW) is now rated as Outperform. Their price target on the stock stands at $74. Citigroup also rated TW as initiated on October 12, 2022, with its price target of $67 suggesting that TW could surge by 3.96% from its current share price. Even though the stock has been trading at $64.75/share, analysts expect it to down by -0.62% to reach $64.35/share.